Type 2 Diabetes Mellitus (T2DM) and Carbohydrate Metabolism in Relation to T2DM from Endocrinology, Neurophysiology, Molecular Biology, and Biochemistry Perspectives

Hilla Mills, Ronald Acquah, Nova Tang, Luke Cheung, Susanne Klenk, Ronald Glassen, Magali Pirson, Alain Albert, Duong Trinh Hoang, and Thang Nguyen Van

1Department of Medical Science, University for Development, Accra, Ghana
2RDLab, The Hospital Institute for Hebal Research, Toluca 50200, MEX, Mexico
3Research Institution of Clinical Biomedicine, Hospital University Medical Centre, Ulm 89000, Germany
4Industrial Research Group, International College of Science and Technology, Route de Lennik 800, CP 590, Brussels 1070, Belgium
5Clinical Analysis Lab, Center of Bio-Medicine, Hanoi, Vietnam

Correspondence should be addressed to Hilla Mills; hilla.mills@hotmail.com, Luke Cheung; luke.cheung@hotmail.com, Ronald Glassen; ronald.glassen@ricbm.de, Alain Albert; alain.albert@ricbm.de, and Thang Nguyen Van; tn.van@cbm.asia

Received 11 July 2022; Revised 15 July 2022; Accepted 18 July 2022; Published 9 August 2022

Copyright © 2022 Hilla Mills et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 2 diabetes mellitus (T2DM) is a severe disease caused by metabolic disorders, particularly carbohydrate metabolism disorders. The disease is a fatal global trouble characterised by high prevalence rates, causing death, blindness, kidney failure, myocardial infarction, amputation of lower limbs, and stroke. Biochemical metabolic pathways like glycolysis, gluconeogenesis, glycogenesis, and glycogenolysis are critical pathways that regulate blood glucose levels with the glucokinase (GK) enzyme playing a central role in glucose homeostasis. Any factor that perturbs the aforementioned biochemical pathways is detrimental. Endocrinological, neurophysiological, and molecular biological pathways that are linked to carbohydrate metabolism should be studied, grasped, and manipulated in order to alleviate T2DM global chaos. The challenge, however, is that, since the body is an integration of systems that complement one another, studying one “isolated” system is not very useful. This paper serves to discuss endocrinology, neurophysiology, and molecular biology pathways that are involved in carbohydrate metabolism in relation to T2DM.

1. Introduction

According to Tramunt et al. [1], diabetes is more prevalent in men, especially in the middle-aged individuals, than in women. This is a general trend all over the world except some few parts like North Africa and the Middle East. The International Diabetes Federation’s last global estimates in 2017 indicated that diabetes prevalence is larger in men than in women (9.1% vs. 8.4%, respectively). This information suggested that approximately 12.3 million more men lived with diabetes than women. The clinical and experimental evidence that support the discrepancies in diabetes prevalence are mainly based on sex hormones endocrinology. The postpubertal sex steroid hormones in particular account for different diabetes prevalence rates in men and women. Premature ovarian sufficiency and early menopause in women correlate with an increased risk of developing T2DM more than premenopausal ones. A documented reduction in diabetic menopausal women incidence of about 21–35% was due to an oestrogen-based hormonal therapy. Hypogonadism men are at risk of developing T2DM and vascular ailments. It is reported that testosterone supplements
improve both glucose and lipid homeostasis. It is beyond dispute that the highlighted endocrinology triggers and influences other biological pathways like glucogenesis, glycolysis, and neuropathways that are associated with homeostasis, particularly glucose and lipid homeostasis. Besides, herbal medicine and nanomaterials have also been used in medical engineering [2, 3].

2. Challenges Associated with T2DM Studies

Gender, as highlighted above, is one of the challenges in treating T2DM. A thorough understanding of male and female physiology in relation to T2DM is imperative. Tramunt et al. [1] asserted that gender governs energy storage and use. Females can withstand undernutrition periods better than males, and this enables females to preserve their reproductive functions. Most importantly, gender determines carbohydrate and lipid metabolism. It is reported that females are more insulin sensitive than males. The list of differences goes on and on. This means glucose and lipid metabolism in men and women is not the same. Tramunt et al. [1] argued that there should be sex-specific medicine for T2DM. Achieving this goal is very expensive considering that research projects are done for men and women separately. This sounds to be the major drawback of the idea of sex-specific T2DM medicine. Notwithstanding, if the goal is achieved, a number of T2DM patients will lead almost a normal life.

Other daunting factors when it comes to T2DM treatment are age, race, health status, and so on. Focusing on health status, recent studies showed that angiotensin-converting enzyme 2 (ACE2) is a receptor of the severe acute respiratory syndrome corona virus (SARS-CoV). The ACE2 is overexpressed in diabetic and hypertension patients due to the use of angiotensin-converting enzyme 1 (ACE1) inhibitors. Consequently, patients suffering from T2DM and hypertension are at risk of acquiring the COVID-19 diseases, and once such patients get sick, death rates for this group are high. It is imperative to monitor glucose levels in SARS-CoV patients. Needless to say, the job is irksome [4]. Studying T2DM is complex considering factors that affect glucose homeostasis. Healthy T2DM animal models are of great help in studying the disease. However, in the world, comorbidity is a great challenge.

According to Timer et al. [5], T2DM affects many body systems like cardiovascular and nervous systems. A plethora of studies revealed that T2DM is a risk factor for vascular dementia and Alzheimer’s disease. Studies that aimed to investigate the correlation between T2DM and cognitive impairment have been done, and they focused on the presence of apolipoprotein allele, mitochondrial malfunction, oxidative stress, macrovascular mechanisms, the formation of advanced glycosylation end-products, inflammation, and insulin resistance [6]. Patients who suffer from diabetic retinopathy showcased a poor cognitive skill compared with disease-free patients. The observation is attributed to microalbuminuria in T2DM patients. Timer et al. [5] conducted a study to compare T2DM-peripheral-neuropathy patients and T2DM-peripheral-neuropathy-free patients concerning cognitive functions based on the notion that peripheral neuropathy may also correlate with microvascular impairment in the brain. The team observed no significant differences between the T2DM patient groups. Such investigations still need to be expanded since only a handful studies have been done. Howbeit, polyneuropathy manifests in the early phases of T2DM, and needless to say, T2DM interferes with the nervous system.

Feng et al. [6] designed an experiment to probe the relationship between TSH (thyroid-stimulating hormone) and serum uric acid (SUA) in T2DM patients with early-stage diabetic kidney disease (ESDKD). A negative correlation of 0.35 (95% confidence interval) between SUA and TSH was reported. This implies that T2DM patients with ESDKD whose SUA levels are high have decreased TSH levels. Uric acid (UA) is produced following purine metabolism. The kidney eliminates about 70% of UA. Recent studies reveal that SUA causes the development of microvascular diseases. According to De Cosmo et al. [8], SUA significantly correlates with albuminuria in T2DM patients. As a result, hyperuricemia has been used as a “biomarker” for DKD prediction. It is documented that thyroid dysfunction can exacerbate glucose metabolism and induce hyperglycaemia in T2DM patients, thus promoting the risk of diabetic complications. Hyperglycaemia lowers the level of thyroid-stimulating hormone (TSH) and mitigates the conversion of thyroxine to triiodothyronine in the peripheral tissues. This piece of evidence without doubt proves that there is a link between endocrinology and T2DM.

According to Stoll et al. [9], secretion of insulin is governed by a circular RNA that contains a lariat sequence of the second intron insulin gene. A decrease in the expression of key components of the secretory machinery of β-cells that leads to impaired glucose or KCl-induced insulin release and calcium signalling was reported following silencing of this intronic circular RNA in pancreatic islets. The effect of the circular RNA was observed to be exerted at the transcriptional level. It is reported that this effect involves an interaction with the RNA-binding protein TAR DNA-binding protein 43 kDa (TDP-43). The level of this circularised intron is mitigated in the islets of rodent diabetes models and of T2DM patients. This is possibly due their impaired secretory capacity. Type 2 diabetes mellitus, therefore, can be studied from a molecular biology perspective.

The xenobiochemistry concept of T2DM with respect to ω-6 PUFA-rich vegetable cooking oil we use almost daily to cook our meals at home is elucidated by Yamashima et al. [10]. Hydroxynonenal is a compound that forms following lipid peroxidation. It is also formed during vegetable oil deep-frying. The phenomenon is frequent when using soybean, rapeseed, and sunflower vegetable oil that contain a lot of linoleic acid. Reactive oxygen species attack membrane ω-6 PUFAs to generate endogenous hydroxynonenal. It is reported that hydroxynonenal forms adducts with 4 amino acids, namely, arginine, lysine, histidine, and cysteine. It is thought that the compound might be able to interfere with proteins. Therefore, hydroxynonenal is capable of causing neuron dysfunction and degeneration by altering membrane-associated glucose and glutamate transporters, ion-
2.1. Carbohydrates. Simple sugars are either monosaccharides or disaccharides that are easy to break down resulting in a rapid increase of blood sugar. Consequently, a rapid secretion of insulin occurs. Examples of such sugars are ribose, fructose, galactose, maltose, glucose, lactose, and sucrose. Sources of such sugars are carbonated beverages, honey, table sugar, fruit juice, candy, and corn syrup [11].

There are sugars that are either disaccharides or polysaccharides having a complex chemical structure. These sugars are not easy to break down, and thus they do not cause a rapid blood sugar escalation following consumption. Sugars such as amylose, dextrin, cellulose, cellobiose, and rutilonulose fall under complex sugars. The sugars are found in foods like apples, brown rice, unrefined whole grains, broccoli, spinach, and lentils. Thousands of glucose units are joined together within starches. The starches fall under complex sugars. Wheat, pasta, potatoes, and chickpeas are sources of starches [11].

Complex carbohydrates that are not digestible belong to this group of sugars. The sugars encourage bacterial growth in the colon. As a result, defecation is made easy. It is reported that fibre is a bulking agent. Pectin, hemicellulose, and cellulose are examples of fibre. Fibre can be soluble or insoluble. Insoluble fibre is known for softening whole grains, brocoli, spinach, and lentils. Thousands of glucose units are joined together within starches. The starches fall under complex sugars. Wheat, pasta, potatoes, and chickpeas are sources of starches [11].

According to Holesh et al. [11], carbohydrate metabolism starts in the mouth where salivary amylase begins to degrade the sugars. Glucose is one of the final products produced following carbohydrate breakdown by the digestive system. The monomers are now ready for absorption. Below are two major monomers discussed.

It is reported that, in normal human beings, approximately 15%–25% of the ingested glucose is metabolised in the liver and the gut. The glucokinase enzyme “activates” glucose by phosphorylation whereby the glucose-carbon-atom on position six links with a phosphate group via its hydroxyl group. This happens in the liver. The glucose-6-phosphate molecule formed undergoes a series of biochemical reactions in a glycolytic pathway to produce two pyruvate molecules. Phosphofructokinase-1 (PFK-1) tightly governs the amount of glucose that undergoes glycolysis. The PFK-1 is inhibited by intracellular excess amounts of ATP (adenosine triphosphate) and citrate. Reports say that the glucose concentration that survives the splanchnic metabolism reaches the systemic circulation. Consequently, a transient increase in the arterial blood glucose level arises from approximately 5 mM/L fasting glucose to 8–10 Mm/L postprandial. Insulin secretion is inevitable therefore, and the arterial glucose is taken up by peripheral organs either independently of insulin (say brain) or under the control of insulin (adipose tissue, skeletal muscle).

Pure fructose ingestion does not trigger insulin secretion or cause markable glycaemia. It is reported that, in case of fructose ingestion, a momentary increase of about 0.5 mM/L in arterial blood glucose takes place. Such a small increment in arterial blood glucose implies that most of glucose is extracted by splanchnic organs. Fructose metabolism takes place mainly in the liver, gut, and kidney. It is reported that, in the aforementioned organs, fructolytic enzymes are present like fructokinase, triokinase, and aldolase B. Fructolysis does not depend on insulin. It is just a biochemical pathway that breaks down fructose to form triose-phosphates viz. dihydroxyacetone phosphate and glyceraldehyde phosphate. Fructokinase and aldolase B are not inhibited by any of the fructolytic products or by signals that arise from cellular energy status [12].

The ingestion of fructose leads to an increment in blood glucose and insulin, compared to an isomolar glucose load. Howbeit, the ingestion of fructose potentiates complete carbohydrate oxidation and energy expenditure in lean healthy volunteers to a larger extent, then in T2DM patients and obese insulin-resistant individuals. In addition, postprandial blood lactic concentrations escalate. The fructolytic pathway converts fructose into lactate and glucose in the splanchnic organs. The glucose produced in the splanchnic organs awaits a secondary oxidation in peripheral tissues. Oral or intravenous fructose boosts glucose synthesis (gluconeogenesis). Surprisingly, glycaemia does not ensue. Also, infusion of gluconeogenic precursors like alanine, lactate, or glyceral leads to gluconeogenesis, but hepatic glucose levels are not affected [12].

2.2. Central Nervous System (CNS) and Carbohydrate Metabolism Studies in Relation to T2DM. Defects in insulin secretion cause a metabolic ailment known as diabetes. In addition, insulin resistance is capable of inducing diabetes [13–15]. Hyperglycaemia is a primary indication of diabetes manifestation caused by an abnormal glucose metabolism. A lot of health complications “come along” with diabetes. Type 2 diabetes mellitus (T2DM) affects quality of life and health of patients intensely owing to its high mortality and prevalence. Pathologically and physiologically, the autonomous nervous system (ANS) might take part in nutrient metabolism. Generally, the sympathetic system could potentiate catabolism, while the parasympathetic system could...
promote anabolism. Evidence is piling up, which support that an escalated sympathetic nervous system activity is associated with pathogenesis of metabolic disorders. Sympathetic denervation improves glucose metabolism and insulin sensitivity; consequently, this implies that the sympathetic nervous system can affect glucose metabolism. When the sympathetic nervous system is activated, acute hyperglycaemia ensues. Such a phenomenon can be prevented by exendin-4. Insulin resistance induced by hypoxia can be relieved by sympathetic nervous system inhibition. Catecholamines mitigate insulin secretion [16, 17].

The prevertebral sympathetic ganglion known as celiac ganglion (CG) and its postganglionic fibres release neurotransmitters like ATP targeting purine receptors [18, 19]. Purine receptors are categorised into two classes, namely P1 and P2. Purinoceptors play a crucial role in the regulation of lipid and glycogen metabolism. In addition to that purinoceptors are involved in the release of insulin [20, 21]. The G-protein-coupled metabolic receptors (P2Y) and the ligand-gated ion channel receptors (P2X) belong to P2 class receptors. The P2Y12 is expressed in both peripheral tissues and central nervous system (CNS). The excitability of sympathetic nerve is controlled by the P2Y12 receptor and is associated with autonomic neuropathy [22]. The receptor might be involved in liver fibrosis, autoimmune pathologies, and platelet aggregation. There is not much information known about the P2Y12 receptor function in nutrient metabolism [16, 23–25]. Table 1 shows P2Y receptor subtypes’ distribution, G-proteins, and agonists.

Table 1: P2Y receptor subtypes’ distribution, G-proteins, and agonists.

| Subtype | Distribution | G-protein | Agonist |
|---------|--------------|-----------|---------|
| P2Y1    | Broad including skeletal tissue, heart, CNS, platelets | Gq | ADP |
| P2Y2    | Brain, kidney, skeletal muscle, heart, lungs | Gq | ATP/UTP |
| P2Y4    | Vascular smooth muscle, lung, placenta | Gq | UTP |
| P2Y6    | Intestines, spleen, lung, heart, placenta, brain, etc. | Gq | UDP |
| P2Y11   | Dendritic cells, intestine, spleen | Gs and Gq | ATP |
| P2Y12   | Hepatocytes, platelets, brain | Gi | ADP |
| P2Y13   | Spleen, brain | Gi | ADP |
| P2Y14   | Haematopoietic cells, intestine, placenta, adipose tissue, heart, brain, etc. | Gi | UDP/UDP-glucose |

Documented reports prove that inflammation plays a key role in the origination and development of a number of metabolic disorders, namely T2DM, obesity, insulin resistance, etc. Neuroinflammation that is related to the autonomic nervous system is capable of contributing to the progression of diabetes. A principal feature of insulin resistance and obesity is presented as a chronic, systemic, low-grade state of inflammation [29, 30]. Activation of inflammasomes is the main molecular mechanism that underlies induction of the inflammatory responses and liver damage under a number of pathological conditions. The pathological conditions include T2DM and development of insulin resistance. There was a suggestion made that inflammasomes link inflammation to insulin resistance [31]. The nod-like receptor protein 3 (NLRP3) inflammasome is a complex that institutes NLRP3, caspase 1, and apoptosis-associated spot-like protein (ASC) [31, 32]. The activation of the NLRP3 inflammasome may lead to cellular inflammatory necrosis and a new kind of a programmed cell death that relies on the activated caspase 1. The above phenomenon is accompanied by the release of proinflammatory factors like interleukin 1-β (IL-1β). Such proinflammatory factors are known for exaggerating inflammatory response and cell dysfunction [16].

Li et al. [16] carried out research on how the P2Y12 receptor is linked to T2DM. The team made use of short hairpin RNA (shRNA) technology to cut down the P2Y12 receptor in T2DM rats and then probed hepatic glycogen content, inflammatory responses, GK expression, celiac ganglia sympathetic activity, and lipid and glucose profiles. The team noted changes in the hepatic P2Y12 receptor expression and in the celiac ganglia. At the mRNA level, P2Y12 receptor expression was significantly higher in rat livers and celiac ganglia in the T2DM rats than in the control group. The T2DM rats were then injected with the P2Y12 shRNA plasmid, and then a significant decrease in P2Y12 mRNA levels was observed. The results show that shRNA could “undo” the high expression of P2Y12 receptor in T2DM rats. In addition, the team observed that the postganglionic celiac sympathetic nerve discharge of the celiac ganglia markedly increased in the T2DM-rat group compared with the control group. The finding suggests that escalated excitability of the celiac sympathetic nerve is a common phenomenon in T2DM. Nevertheless, treatment with P2Y12 shRNA plasmid normalises the situation. Moreover, principal typical features of metabolic disorders were observed at the early stage of T2DM. Fasting blood glucose (FBG) and fasting plasma insulin (FINS) levels were higher in T2DM rats than in control. In contrast, FINS and FBG levels in T2DM rats treated with the P2Y12 shRNA...
plasmid were significantly lower. The finding implies that P2Y12 shRNA treatment could normalise changes in FBG and FINS levels and improve insulin resistance in T2DM rats. Furthermore, it was observed that P2Y12 shRNA treatment reduced levels of triglyceride, total cholesterol, and LDL in T2DM rats. A lower hepatic glycogen profile was observed in T2DM rats. Howbeit, upon treatment with the P2Y12 shRNA, the hepatic glycogen significantly increased. A lower hepatic expression of GK mRNA was observed from RT-PCR analysis in the T2DM rats than in the control group. In contrast, hepatic GK mRNA levels in T2DM rats treated with P2Y12 shRNA increased significantly. Western blot results revealed lower GK protein levels in T2DM rats than that in control rats. The GK levels increased upon P2Y12 shRNA treatment. Also, Western blot analysis showed that hepatic NK-κβ p65 levels were higher in T2DM rats than in the control group. A markable decease in the hepatic NF-κβ p65 levels were noted upon treatment of T2DM rats with the P2Y12 shRNA. Finally, the team examined the effects of P2Y12 shRNA on NLRP3 inflammasome and interleukin-1β (IL-1β) in T2DM rats. The observation was that, at both mRNA and protein levels, the expression of NLRP3 subunits (ASC, NLRP, and caspase-1) and IL-1β was increased substantially in T2DM rats compared with the control group. Notwithstanding, P2Y12 shRNA treatment reversed the escalated levels of NLRP3 and IL-1β, exhibiting the beneficial properties of P2Y12 shRNA in playing an inhibitory role of IL-1β production and NLRP3 inflammasome. Figure 2 shows the P2Y12 receptor allows the entrance of a signal from excited CG.

Glucagon is a glucose-elevating hormone that is secreted by pancreatic alpha-cells in the event that blood glucose concentration falls. The hormone then triggers a cascade of biochemical signalling pathways in the hepatocytes that stimulate glucogenesis. The glucose produced then supports the fallen blood glucose level to normalise. Extrinsic electric signals from the parasympathetic and sympathetic ANS also stimulate glucagon secretion. A combination of intrinsic mechanisms, paracrine and juxtacrine, suppress glucagon secretion under normoglycaemic conditions.
Hypoglycaemia induces glucagon secretion by a mechanism that involves a fall in the ATP/ADP cytosolic ratio and escalated activity of P/Q-type Ca\(^{2+}\) channels, causing Ca\(^{2+}\) influx. These findings illustrate the crucial vitality of the electrophysiological mechanisms that link glucose metabolism to electrical activity and hormone secretion [33]. Basco et al. [34] conducted an experiment using mice with alpha-cell-specific knockout GK genes. The findings illustrated the crucial role of GK in regulating glucagon secretion from intact islets and invivo. Honzawa et al. [35] came up with a different suggestion concerning glucose-dependent intrinsic mechanism for the control of glucagon secretion. The team mentioned that glucose uptake by sodium-glucose co-transporter 1 (SGLT1) can cause intracellular Na\(^{+}\) ion concentrations to be a higher than that of the extracellular compartment. Consequently, secretion of glucagon is triggered. This mechanism is deemed relevant particularly for the paradoxical hypersecretion of glucagon in T2DM. A lot of scientific reports serve as evidence to illustrate that alpha-cells in intact cells are capable of responding to hypoglycaemia by releasing glucagon. In addition, the importance of GK during such phenomena is also documented. Notwithstanding, it is still ambiguous whether alpha-cells are capable of regulating secretion of glucagon intrinsically and whether GK is the glucose sensor linking glucose metabolism to the regulation of glucagon secretion [33]. Moede et al. [33] addressed the above unanswered questions by conducting an experiment where they manipulated GK activity and expression in purified single alpha-cells accompanied with measurements of glucagon release by total internal reflection fluorescence (TIRF) microscopy. In 1996, GK expression in alpha-cells has been done. However, the findings are debatable since the sample that was analysed contained approximately 87% alpha-cells and the rest were other kinds of cells, including beta-cells, which would be suffice to detect GK transcripts. Moede and colleagues managed to obtain 96.6 ± 14% purity of the functional rat alpha-cells. The team examined the hexokinase isoforms that were expressed in rat pancreatic alpha-cells. The results came out as expected: cells that were identified as β-cells were positive for GK and negative for hexokinase I, II, and III expression. The most important observation was that all α-cells analysed tested positive for GK. Pancreatic alpha-cells were found to express the neuroendocrine GK isoform. Verification of this finding was done by isolating RNA from sorted alpha-cells and performing real-time polymerase chain reaction (RT-PCR).
using primers located in the first and seventh exons [36]. The resulted PCR products were subcloned and sequenced. The sequence analysis showed that 60% GK mRNA is encoding the functional B1 neuroendocrine isoform [37]. The rest, that is, 40%, encode neuroendocrine GK nonfunctional variants. Heimberg et al. [38] and Segerstolpe et al. [39] support Moede et al. [33] findings.

The GK enzyme has become a primary target in treating T2DM. Permanent neonatal diabetes mellitus is a severe ailment that occurs as a result of homozygous inactivating mutations in GK. Heterozygous inactivating mutations elevate the threshold for insulin secretion [40, 41]. Glucose kinase regulatory protein (GKRP), as the name says, is a protein that regulates GK in the hepatocytes. The GKRP binds the GK, hence switching off the glycolytic pathway in the event of hypoglycaemia. Many research articles highlight that GKRP mutations that affect its activity, localisation, and expression do not only have impact on glucose homeostasis but also on triglyceride (TG) metabolism [42, 43]. A number of small molecules that serve as GK activators (GKAs) have been found and used in the medical field. Notwithstanding, the activators posed some disadvantageous effects like loss of efficacy over time, increase in TG concentrations, and hypoglycaemia [44, 45]. These effects were linked to ongoing activation of β-cells and peradventure related to the development of hepatic steatosis [46–48]. Figure 3 shows glucokinase (GK) phosphorylates glucose during glycolysis.

Patients with GK-activating mutations or GKRP loss-of-function mutations require hepatoselective GKAs that affect neither the GK-GKRP interactions nor GK in β-cells. Such “ideal” small-molecule activators can circumvent the adverse effects posed by the GKAs, which have been used in the medical field. Therefore, Vella et al. [48] developed a hepatoselective GKA namely TTP399. The GKA improved glycaemic regulation both in T2DM animal models and patients. Adverse effects like dyslipidaemia, hypoglycaemia, and pathological accumulation of glycogen and TG in the liver were not induced. In addition, TTP339 administration did not seem to perturb GK-GKRP interactions in the presence of normoglycaemia, maybe thus justifying the absence of altered liver function and dyslipidaemia. There was a reduction in hepatic fat in response to TTP399 administration [48].

Hexokinase isoenzyme, known as glucokinase (GK), is expressed specifically in pancreatic islet beta-cells and mature hepatocytes [49, 50]. The GK is a pacemaker enzyme in a glycolytic pathway. It catalyses the first irreversible reaction of glycolysis. The enzyme adds a phosphate group to the carbon atom number six of a glucose molecule, forming glucose-6-phosphate. The product formed can then be metabolised further and stored as glycogen in the liver for future use. GK plays a vital role in regulating glycosylation and gluconeogenesis in the liver. Therefore, abnormalities in the structure and function of the GK enzyme definitely cause metabolic disorders like T2DM [16].

There is what is referred to as diet-induced diabetes [54, 55]. Scientists have been studying T2DM using high-fat-diet (HFD)-fed mouse models. GK expression in β-cells decreased in HFD-induced diabetes according to Lu et al. [27]. Nevertheless, the contribution of decreased GK expression to HFD-induced diabetes is ambiguous. It is reported that HFD-induced defect in β-cell function is associated with the downregulation of islet GK. HFD feeding decreases GK mRNA and GK protein by approximately 45%, compared with isoenergetic high-carbohydrate feeding in rats. Previous ex vivo studies of islets also showed a decrease in GK mRNA and GK protein following co-culture with palmitic acid [51]. Patients with T2DM were found to have reduced GK expression in the islets [22, 55, 56]. The challenge, however, is that GK is expressed in both hepatocytes and β-cells. Therefore, probing the correlation between GK expression and HFD is daunting [57]. Table 2 shows comparison between hexokinase and glucokinase (GK) enzymes.

Regardless of a challenge highlighted above, Lu et al. [57] designed an experiment where they targeted a β-cell gene, transferred it into a vector, and then investigated β-cell-specific GK expression on β-cell function in HFD-induced diabetes. The team made use of the adeno-associated viral (AAV) vector system. The crew observed that overexpression of GK promoted glycolytic flux, activation of ATP-sensitive potassium channel, membrane depolarisation, and an increase in proliferation of Min6 cells. The transduction of β-cell GK showed no difference in terms of glucose handling in chow-fed C57BL/6 mice. Adult mice fed with a HFD were found to have reduced islet GK expression, glucose-stimulated insulin secretion (GSIS), and impaired glucose tolerance. Nevertheless, β-cell-targeted GK transduction reinstated GSIS and improved glucose tolerance. Perfusion experiments of the islets confirmed
restoration of GSIS in isolated HFD islets upon GK gene transduction.

2.3. Mechanisms. Based on the studies conducted by Lu et al. [57], restoration of β-cell function by β-cell-targeted GK overexpression suggests that GK suppression plays an etiological role in β-cell dysfunction in HFD-induced diabetes. It is thought that this mechanism is most likely to be regulated through PDX-1, which plays a regulatory role in GK expression [58]. The PDX-1 is downregulated in diabetic victims [59]. A decrease in PDX-1 expression, which leads to reduced GK expression, was observed in rat islets that were incubated in fatty acids. Restoration of GK expression increases glycolytic flux and leads to the induction of glucose utilization [58, 60, 61]. The mechanism behind increased glycolytic flux by overexpression of the GK is vague. Howbeit, glucose plays a regulatory role in β-cell proliferation and GSIS [62, 63]. Overexpression of β-cell GK above physiological levels in chow-fed β-cells increased glucose utilisation. Glucose induces β-cell proliferation via IRS2 and cyclin D2 [64].

According to Vella et al. [48], GK is the target enzyme for T2DM treatment due to the vital role it plays in glucose homeostasis. A number of GKAs have been designed, assessed, and evaluated. At least 30 GKAs are discussed in published preclinical data. GKAs studies in humans and animals showed hypoglycaemia and enhanced β-cell function and proliferation. Nonetheless, the clinical trials did not come out well due to adverse effects like hyperlipidaemia, hypoglycaemia, and declining efficacy after prolonged treatment [65]. The proposed mechanism of the above highlighted side effects is that hepatic overexpression escalates hepatic lipogenesis and plasma triglycerides levels in rats [66]. GkAs can be categorised into GkAs that target the pancreas and liver, hepato-selective GkAs and partial GkAs. Vella and colleagues studied a hepatoselective GKA, TTP399. It is proposed that GK-GKRP interaction is maintained in the presence of TTP399. The TTP399 increased the GK activity in its active conformation. Consequently, TG levels are kept normal. Heavier individuals lost weight upon administration of TTP399. The mechanism underlying this finding requires further studies, including the potential impacts of TTP399 on food intake and appetite.

Reversal of fasting plasma glucagon is a mystery in relation to the study of Vella et al. [48]. Insulin secretion impairment has been the explanation for increased plasma glucagon levels. Notwithstanding, a number of scientists challenged this idea and suggested that insulin signalling impairment explains the elevation of plasma glucagon levels [67]. According to Lee et al. [64], the accumulation of ceramide in α-cells of ob/ob hyperglycaemic rodents inhibits the suppression of glucagon. The reduction in FBG levels by the TTP399 therapy with no changes in insulin concentrations suggests an improvement in the action of insulin. It is ambiguous if the mechanism highlighted above explains the reduction in fasting glucagon. Needless to say, further studies should be conducted.

According to Li et al. [16], hepatic P2Y12 receptor protein expression was increased in the T2DM rats and the inhibition of the protein (P2Y12) by P2Y12 shRNA caused restoration of glycogen content in the liver. The finding suggests that P2Y12 might be involved in the hepatic dysfunction pathogenesis in diabetic rats. Cell bodies of the sympathetic neurons in the celiac ganglia (CG) project axons to the liver, indicating that the neurotransmission across CG may activate the sympathetic afferents of the liver. The solution, therefore, is the downregulation of the P2Y12 receptor protein expression in both the CG and liver, resulting in the inhibition of the unusual sympathetic excitability, promotion of hepatic glycogenesis, and normalisation of hyperglycaemia. The NLRP3 subunits (ASC, NLRP, and caspase-1) that assemble and activate NLRP3 complex were increased in T2DM rats. This finding is most likely explained by upregulated P2Y12 in the liver of T2DM rats since P2Y12 shRNA mitigated the increments of ASC, active caspase-1, and NLRP. In addition, NF-κB plays a vital role in the inflammatory responses and might be involved in the activation of the NLRP3 inflammasome. Activation of NLRP3 inflammasome complex induces the secretion of IL-1β, leading to cell injury and pyroptosis. The P2Y12 shRNA therapy suppressed IL-1β release. Therefore, a downregulation of sympathetic purinergic excitability could prevent hepatic inflammation of the T2DM rats, thereby improving dysfunctional metabolism and hepatic insulin resistance [32].

### 3. Conclusions

Type 2 diabetes mellitus (T2DM) is caused by a number of factors namely gene mutations that lead to "under-expression" or overexpression of the GK, GKRP, glucagon, insulin, and PDX-1; β-cell dysfunction, hepatic inflammation, unusual excitability of sympathetic nerves, and diet-inducing factors like taking high fat content. Molecular therapy is a promising potent solution to T2DM since the P2Y12 shRNA treatment in T2DM rats mitigated a P2Y12 receptor expression at the mRNA level significantly; increased postganglionic sympathetic nerve discharge (SN); normalised FBG and FINS; improved insulin resistance, triglyceride (TG) levels, total cholesterol (TC) levels, and the reduction in fasting glucagon. Needless to say, further studies should be conducted.

### Table 2: Comparison between hexokinase and glucokinase (GK) enzymes.

| Attributes                  | Hexokinase                        | GK                          |
|-----------------------------|-----------------------------------|------------------------------|
| Biological importance       | Intracellular glucose homeostasis | Blood glucose homeostasis    |
| Clinical significance       | Deficiency results in haemolytic anaemia | Low activity in diabetic patients |
| Inducibility                | Not inducible                      | Determined by the insulin in the liver |
| Substrate affinity $V_{max}$| Higher ($K_m = 0.05$ Mm/L)         | Lower ($K_m = 10$ Mm/L)      |

According to Li et al. [16], hepatic P2Y12 receptor protein expression was increased in the T2DM rats and the inhibition of the protein (P2Y12) by P2Y12 shRNA caused restoration of glycogen content in the liver. The finding suggests that P2Y12 might be involved in the hepatic dysfunction pathogenesis in diabetic rats. Cell bodies of the sympathetic neurons in the celiac ganglia (CG) project axons to the liver, indicating that the neurotransmission across CG may activate the sympathetic afferents of the liver. The solution, therefore, is the downregulation of the P2Y12 receptor protein expression in both the CG and liver, resulting in the inhibition of the unusual sympathetic excitability, promotion of hepatic glycogenesis, and normalisation of hyperglycaemia. The NLRP3 subunits (ASC, NLRP, and caspase-1) that assemble and activate NLRP3 complex were increased in T2DM rats. This finding is most likely explained by upregulated P2Y12 in the liver of T2DM rats since P2Y12 shRNA mitigated the increments of ASC, active caspase-1, and NLRP. In addition, NF-κB plays a vital role in the inflammatory responses and might be involved in the activation of the NLRP3 inflammasome. Activation of NLRP3 inflammasome complex induces the secretion of IL-1β, leading to cell injury and pyroptosis. The P2Y12 shRNA therapy suppressed IL-1β release. Therefore, a downregulation of sympathetic purinergic excitability could prevent hepatic inflammation of the T2DM rats, thereby improving dysfunctional metabolism and hepatic insulin resistance [32].
hepatic glycogen; and reduced NLRP3 complex expression. GKAs are also another good option, particularly hepatoselective GKA like TTP399.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
HM and RA contributed to conception and design of the study and wrote the first draft of the manuscript. NT, LC, SK, RG, MP, AA, DTH, and TNV contributed to the data collection and analysis. All the authors approved the submitted version.

Acknowledgments
This work was supported by Hospital University Medical Centre.

References
[1] B. Tramunt, S. Smati, N. Grandgeorge et al., “Sex differences in metabolic regulation and diabetes susceptibility,” Diabetologia, vol. 63, no. 3, pp. 453–461, 2020.
[2] M. Xu, H. Zhang, T. Tang et al., “Potential and applications of capillary electrophoresis for analyzing traditional Chinese medicine: a critical review,” The Analyst, vol. 146, no. 15, pp. 4724–4736, 2021.
[3] R. Zhao, J. Xiang, B. Wang, L. Chen, and S. Tan, “Recent advances in the development of noble metal NPs for cancer therapy,” Bioorganic Chemistry, vol. 2022, Article ID 2444516, 14 pages, 2022.
[4] C. Cristelo, C. Azevedo, J. M. Marques, R. Nunes, and B. Sarmento, “SARS-CoV-2 and diabetes: new challenges for the disease,” Diabetes Research and Clinical Practice, vol. 164, Article ID 108228, 2020.
[5] S. M. Timer, E. Timer, N. P. Yükselen, and M. C. Göküş göz, “The relationship between polyneuropathy and cognitive functions in type 2 diabetes mellitus patients,” Sisli Elif Hastanesi Tip Bilimleri, vol. 54, no. 1, pp. 41–46, 2020.
[6] W. Q. Zhao and M. Townsend, “Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease,” Biochimia et biophysica acta, vol. 1792, no. 5, pp. 482–496, 2009.
[7] X. Feng, J. Huang, Y. Peng, and Y. Xu, “Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease,” BMC Endocrine Disorders, vol. 21, pp. 1–8, 2021.
[8] S. De Cosmo, F. Viazzi, A. Pacilli et al., “Serum uric acid and risk of dxd in type 2 diabetes,” Clinical Journal of the American Society of Nephrology: CJASN, vol. 10, no. 11, pp. 1921–1929, 2015.
[9] L. Stoll, A. Rodriguez-Trejo, C. Guay et al., “A circular RNA generated from an intron of the insulin gene controls insulin secretion,” Nature Communications, vol. 11, pp. 5611–5613, 2020.
[10] T. Yamashita, T. Ota, E. Mizukoshi et al., “Intake of n-6 polyunsaturated fatty acid-rich vegetable oils and risk of lifestyle diseases,” Advances in Nutrition, vol. 11, no. 6, pp. 1489–1509, 2020.
[11] J. E. Holesh, S. Aslam, and A. Martin, Physiology, Carbohydrates, StatPearls, 2021, https://www.ncbi.nlm.nih.gov/books/NBK459280/.
[12] L. Tappy, “Metabolism of sugars: a window to the regulation of glucose and lipid homeostasis by sphingolipid organs,” Clinical Nutrition, vol. 40, no. 4, pp. 1691–1698, 2021.
[13] R. C. W. Ma and J. C. N. Chan, “Type 2 diabetes in east Asians: similarities and differences with populations in Europe and the USA,” Annals of the New York Academy of Science, vol. 1281, no. 1, pp. 64–91, 2013.
[14] D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, “IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030,” Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311–321, 2011.
[15] Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” JAMA, vol. 310, no. 9, p. 948, 2013.
[16] L. Li, J. Yang, B. Liu et al., “P2Y12 shRNA normalizes inflammatory dysfunctional hepatic glucokinase activity in type 2 diabetic rats: inflammatory dysfunctional hepatic glucokinase activity in type 2 diabetic rats,” Biomedicine & Pharmacotherapy, vol. 132, Article ID 110803, 2020.
[17] D. Pérez-Tilve, L. González-Matias, B. A. Aulingier et al., “Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system,” American Journal of Physiology-Endocrinology and Metabolism, vol. 298, no. 5, pp. E1088–E1096, 2010.
[18] G. Burnstock, “P2X receptors in the gut, WIREs,” Membrane Transport and Signal, vol. 1, no. 3, pp. 269–279, 2012.
[19] E. M. Silinsky and V. Gerzanich, “On the excitatory effects of ATP and its role as a neurotransmitter in coeliac neurons of the guinea-pig,” The Journal of Physiology, vol. 464, no. 1, pp. 197–212, 1993.
[20] G. Burnstock and I. Novak, “Purinergic signalling in the pancreas in health and disease,” Journal of Endocrinology, vol. 213, no. 2, pp. 123–141, 2012.
[21] G. Burnstock, B. Vaughn, and S. C. Robson, “Purinergic signalling in the liver in health and disease,” Purinergic Signalling, vol. 10, no. 1, pp. 51–70, 2014.
[22] J. Guo, X. Sheng, Y. Dan et al., “Involvement of P2Y12 receptor of stellate ganglion in diabetic cardiovascular autonomic neuropathy,” Purinergic Signalling, vol. 14, no. 4, pp. 345–357, 2018.
[23] C. Qin, J. Zhou, Y. Gao et al., “Critical role of P2Y12 receptor in regulation of Th17 differentiation and experimental autoimmune encephalomyelitis pathogenesis,” The Journal of Immunology, vol. 199, no. 1, pp. 72–81, 2017.
[24] H. H. Satti, E. F. Khaleel, R. M. Badi, A. O. Elrefaie, and D. G. Mostafa, “Antiplatelet activity of astaxanthin in control and high cholesterol-fed rats mediated by downregulation of P2Y12, inhibition of NF-kB, and increasing intracellular levels of camp,” Platelets, vol. 32, no. 4, pp. 469–478, 2020.
[25] K. Schwarzkopf, J. Bojunga, S. Rüschenaub et al., “Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease,” Hepatology Communications, vol. 2, no. 12, pp. 1601–1609, 2018.
[26] N. Joshi, A. K. Kopec, J. L. Ray, and J. P. Luyendyk, “Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease,” Toxicology, vol. 365, pp. 9–16, 2016.
Evidence-Based Complementary and Alternative Medicine

[27] T. Jia, J. Rao, L. Zou et al., “Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia,” *Frontiers in Neuroscience*, vol. 11, p. 755, 2017.

[28] Y. Zhang, J. Peti-Peterdi, C. E. Müller et al., “P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus,” *Journal of the American Society of Nephrology*, vol. 26, no. 12, pp. 2978–2987, 2015.

[29] C. Han, M. W. Rice, and D. Cai, “Neuroinflammatory and autonomic mechanisms in diabetes and hypertension,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 311, no. 1, pp. E32–E41, 2016.

[30] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance in fat plays a crucial role in the development of obesity-related insulin resistance,” *Journal of Clinical Investigation*, vol. 112, no. 12, pp. 1821–1830, 2003.

[31] B. Vandamnagsar, Y. H. Youm, A. Ravussin et al., “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,” *Nature Medicine*, vol. 17, no. 2, pp. 179–188, 2011.

[32] N. Kelley, D. Jeltema, Y. Duan, and Y. He, “(Q₇₄) NLRP3 inflammasome: an overview of mechanisms of activation and regulation inflammasome: an overview of mechanisms of activation and regulation,” *International Journal of Molecular Sciences*, vol. 20, no. 13, p. 3328, 2019.

[33] T. Moede, B. Leibiger, P. Vaca Sanchez et al., “Glucokinase intrinsically regulates glucose sensing and glucagon secretion in pancreatic alpha cells,” *Scientific Reports*, vol. 10, no. 1, Article ID 20145, 2020.

[34] D. Basco, Q. Zhang, A. Salehi et al., “α-cell glucokinase suppresses glucose-regulated glucagon secretion,” *Nature Communications*, vol. 9, no. 1, p. 546, 2018.

[35] N. Honzawa, K. Fujimoto, and T. Kitamura, “Cell autonomous dysfunction and insulin resistance in pancreatic α-cells,” *International Journal of Molecular Sciences*, vol. 20, no. 15, p. 3699, 2019.

[36] I. Roncero, E. Alvarez, P. Vázquez, and E. Blázquez, “Functional glucokinase isoforms are expressed in rat brain,” *Journal of Neurochemistry*, vol. 74, no. 5, pp. 1848–1857, 2000.

[37] F. M. Matschinsky, M. A. Magnuson, D. Zelent et al., “The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy,” *Diabetes*, vol. 55, pp. 1–12, 2006.

[38] H. Heimberg, A. De Vos, D. Pipeleers, B. Thorens, and F. Schuit, “Differences in glucose transporter gene expression between rat pancreatic α- and β-cells are correlated to differences in glucose transport but not in glucose utilization,” *Journal of Biological Chemistry*, vol. 270, no. 15, pp. 8971–8975, 1995.

[39] A. Segerstolpe, A. Palasantza, P. Eliasson et al., “Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes,” *Cell Metabolism*, vol. 24, no. 4, pp. 593–607, 2016.

[40] L. Agius, “Glucokinase and molecular aspects of liver glycogen metabolism,” *Biochemical Journal*, vol. 414, pp. 1–18, 2008.

[41] M. M. Byrne, J. Sturis, K. Clement et al., “Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations,” *Journal of Clinical Investigation*, vol. 93, no. 3, pp. 1120–1130, 1994.

[42] N. L. Beer, N. D. Tribble, L. J. McCulloch et al., “‘The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver,” *Human Molecular Genetics*, vol. 18, no. 21, pp. 4081–4088, 2009.

[43] M. Vaxillaire, C. Cavalcanti-Proenca, A. Dechaume et al., “The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population,” *Diabetes*, vol. 57, no. 8, pp. 2253–2257, 2008.

[44] A. S. Grewal, B. S. Sekhon, and V. Lather, “Recent updates on glucokinas activators for the treatment of type 2 diabetes mellitus,” *Mini-Reviews in Medicinal Chemistry*, vol. 14, no. 7, pp. 585–602, 2014.

[45] L. Katz, N. Manamley, W. J. Snyder et al., “AMG 151 (ARRY-403), a novel glucokinase activator, increases fasting and postprandial glycaemia in patients with type 2 diabetes,” *Diabetes, Obesity and Metabolism*, vol. 18, pp. 191–195, 2016.

[46] C. Hallé, D. J. Lloyd, A. Pellacani, and M. M. Véniant, “Molecular targeting of the GK-GKRP pathway in diabetes,” *Expert Opinion on Therapeutic Targets*, vol. 19, no. 1, pp. 129–139, 2015.

[47] A. Raimondo, M. G. Rees, and A. L. Glynn, “Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism,” *Current Opinion in Lipidology*, vol. 26, no. 2, pp. 88–95, 2015.

[48] A. Vella, J. L. R. Freeman, I. Dunn, K. Keller, J. B. Buse, and C. Valcarce, “Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator,” *Science Translational Medicine*, vol. 11, no. 475, Article ID eaau3441, 2019.

[49] R. A. Haessler, S. Camastra, B. Astiarraga, M. Nannipieri, M. Anselmino, and E. Ferrannini, “Decreased expression of hepatic glucokinase in type 2 diabetes,” *Molecular Metabolism*, vol. 4, no. 3, pp. 222–226, 2015.

[50] M. Song, L. Zou, L. Peng et al., “LncRNA NONRATT021972 siRNA normalized the dysfunction of hepatic glucokinase through AKT signaling in T2DM rats,” *Endocrine Research*, vol. 42, no. 3, pp. 180–190, 2017.

[51] M.-L. Peyot, E. Pepin, J. Lamontagne et al., “β-cell failure in diet induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced β-cell mass,” *Diabetes*, vol. 59, no. 9, pp. 2178–2187, 2010.

[52] M. S. Winzell and B. Ahrén, “The high-fat diet-fed mouse: a model for studying mechanisms and treatments of impaired glucose tolerance and type 2 diabetes,” *Diabetes*, vol. 53, no. 3, pp. S215–S219, 2004.

[53] Y. Yoshikawa, E. Ueda, H. Miyake, H. Sakurai, and Y. Kojima, “Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus,” *Biological and Bioophysical Research Communications*, vol. 281, no. 5, pp. 1190–1193, 2001.

[54] S. Gremlich, C. Bonny, G. Waeger, and B. Thorens, “Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinasine, insulin, and somatostatin levels,” *Journal of Biological Chemistry*, vol. 272, no. 48, pp. 30261–30269, 1997.

[55] S. Del Guerra, R. Lupi, L. Marselli et al., “Functional and molecular defects of pancreatic islets in human type 2 diabetes,” *Diabetes*, vol. 54, no. 3, pp. 727–735, 2005.

[56] J. Taneera, S. Lang, A. Sharma et al., “A systems-genetics approach identifies genes and pathways for type 2 diabetes in
human islets,” *Cell Metabolism*, vol. 16, no. 1, pp. 122–134, 2012.

[57] B. Lu, K. Kurmi, M. Munoz-Gomez et al., “Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes,” *Disease Models & Mechanisms*, vol. 11, no. 6, Article ID dmm033316, 2018.

[58] H. Watada, Y. Kajimoto, Y. Umayahara et al., “The human glucokinase gene β-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells,” *Diabetes*, vol. 45, no. 11, pp. 1478–1488, 1996.

[59] J. Taneera, P. Storm, and L. Groop, “Downregulation of type II diabetes mellitus and maturity onset diabetes of young pathways in human pancreatic islets from hyperglycemic donors,” *Journal of Diabetes Research*, vol. 2014, pp. 1–7, 2014.

[60] F. Schuit, D. Flamez, A. de Vos, and D. Pipeleers, “Glucose-regulated gene expression maintaining the glucose-responsive state of β-cells,” *Diabetes*, vol. 51, no. 3, pp. S326–S332, 2002.

[61] G. C. Webb, M. S. Akbar, C. Zhao, and D. F. Steiner, “Expression profiling of pancreatic β cells: glucose regulation of secretory and metabolic pathway genes,” *Proceedings of the National Academy of Sciences*, vol. 97, no. 11, pp. 5773–5778, 2000.

[62] S. Porat, N. Weinberg-Corem, S. Tornovsky-Babaey et al., “Control of pancreatic β cell regeneration by glucose metabolism,” *Cell Metabolism*, vol. 13, no. 4, pp. 440–449, 2011.

[63] S. J. Salpeter, A. Klochendler, N. Weinberg-Corem et al., “Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels,” *Endocrinology*, vol. 152, no. 7, pp. 2589–2598, 2011.

[64] R. E. Stamateris, R. B. Sharma, Y. Kong et al., “Glucose induces mouse β-cell proliferation via IRS2, MTOR, and cyclin D2 but not the insulin receptor,” *Diabetes*, vol. 65, no. 4, pp. 981–995, 2016.

[65] L. Agiús, “Lessons from glucokinase activators: the problem of declining efficacy,” *Expert Opinion on Therapeutic Patents*, vol. 24, no. 11, pp. 1155–1159, 2014.

[66] R. M. O’Doherty, D. L. Lehman, S. Télémaque-Potts, and C. B. Newgard, “Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia,” *Diabetes*, vol. 48, no. 10, pp. 2022–2027, 1999.

[67] S. Sharma and P. Tripathi, “Gut microbiome and type 2 diabetes: where we are and where to go?” *The Journal of Nutritional Biochemistry*, vol. 63, pp. 101–108, 2019.

[68] Y. Lee, E. D. Berglund, X. Yu et al., “Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells,” *Proceedings of the National Academy of Sciences of the USA*, vol. 111, no. 36, pp. 13217–13222, 2014.